A double-blind, randomized, controlled, clinical trial to evaluate the efficacy and safety of MSC (mesenchymal stromal cells) intravenous administration in patients with COVID-induced ARDS compared to a control arm.
All trial participants will receive SOC\*.
Randomization will be 1:1 between:
* Treatment arm: allogenic MSC.
* Control arm: Placebo (solution with the same composition as the experimental treatment, without the MSC).
* SOC can include any medicines that are being used in clinical practice (e.g. lopinavir/ritonavir; hydroxy/chloroquine, tocilizumab, etc.).
